Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Assets Average (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Assets Average for 4 consecutive years, with $249.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 34.74% to $249.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $249.7 million, a 34.74% decrease, with the full-year FY2025 number at $318.7 million, down 19.53% from a year prior.
  • Assets Average was $249.7 million for Q4 2025 at Phathom Pharmaceuticals, up from $245.3 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $385.2 million in Q1 2024 to a low of $154.4 million in Q1 2023.
  • A 4-year average of $271.3 million and a median of $251.0 million in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 149.45% in 2024, then crashed 34.74% in 2025.
  • Phathom Pharmaceuticals' Assets Average stood at $183.4 million in 2022, then surged by 77.46% to $325.4 million in 2023, then grew by 17.6% to $382.7 million in 2024, then tumbled by 34.74% to $249.7 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Assets Average are $249.7 million (Q4 2025), $245.3 million (Q3 2025), and $272.2 million (Q2 2025).